Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALL SCTped 2012 FORUM
2024-512657-24-00Phase 3Authorised
- Sponsor
- St. Anna Children's Cancer Research Institute
- Start
- Oct 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 24
01
Overview
Phase 3 trial of blinatumomab in acute lymphoblastic leukemia (ALL), sponsored by St. Anna Children's Cancer Research Institute. Primary endpoints: Overall Survival (Stratum 1) and Event-Free Survival (Stratum 2). Planned start Oct 2024; status: authorised.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2024-512657-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512657-24-00.